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Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen
for diffuse Large B –cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL
remains uncertain. FCR (fludarabine, cyclophosphamide, rituximab) has been shown to be better than fludarabine
alone and fludarabine plus cyclophosphamide for IL. In FOLL05 trial, R-CHOP was compared with R-CVP
(cyclophosphamide, vincristine, prednisone) and R-FM (fludarabine, mitoxantrone). The study showed that R-CHOP
appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (bendamustine, rituximab) has
longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary
malignancies between the two regimens appear to be comparable. In this review, new combination regimens
reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.Rituximab has essentially changed the natural history of
diffuse Large B –cell lymphoma (DLBCL) [1-7]. R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) remains the standard frontline regimen for
DLBCL [8-11]. New agents and biomarkers are being
studied in an attempt to improve upon the current effi-
cacy of R-CHOP [12-19]. Meanwhile, indolent lymphoma,
the second most common subtype of lymphoma, remains
incurable with chemotherapy alone [20-23]. FCR (fludara-
bine, cyclophosphamide, rituximab) has been shown to be
better than fludarabine alone and fludarabine plus cyclo-
phosphamide for untreated chronic lymphoid leukemia
(CLL) [24-26]. Another regimen, PCR (pentostatin, cyclo-
phosphamide, rituximab), was found to be comparable to
FCR for untreated CLL[21]. In this review, new combin-
ation regimens reported at 2012 ASCO annual meeting
were evaluated for frontline and salvage therapy of indo-
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reproduction in any medium, provided the orRituximab for low burden indolent lymphoma
For low burden indolent lymphoma (LBIL), the standard
approach is still “watch & wait”. A randomized study
was conducted for low burden IL, the E4402 RESORT
study [27]. The hypothesis was that rituximab (R) treat-
ment of LBIL and maintenance rituximab (MR) would
be superior to rituximab retreatment at disease progres-
sion. LBIL (small lymphocytic lymphoma, MZL, FL)
were treated with R weekly x 4, then responders were
randomized to receive MR (R x 1 q 3 months until pro-
gression), or RR (R weekly x 4 at progression). The pri-
mary endpoint was time to treatment failure (TTF). At
the 2011 ASH meeting update, 384 with FL were en-
rolled. Overall response (CR +PR) was 71%. These 274
responders were then randomized to MR (n = 140) or
RR (n = 134). The median follow-up was 3.8 yrs. There
was no significant difference in TTF between the two
groups (MR 3.9 yr vs. RR 3.6 yr). At 3 yrs, the rate of
time to cytotoxic chemotherapy (TTTC) was 95% for
MR vs. 86% for RR patients (p = .027). Therefore, MR
and RR were comparable for the primary endpoint, TTF.
The E4402 results on non-FL lymphomas (SLL, MZL)
were presented at 2012 ASCO [28]. A total of 137 non-
FL patients were enrolled. Overall response (CR+PR)
was 41% (n = 57). These 57 patients were thentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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follow-up was 4.3 yrs. TTF of MR group was better than
that of RR group (MR 3.74 yr vs. RR 1.07 yr, p = 0.0002;
HR 4.95). At 3 yrs, the rate of freedom from cytotoxic
treatment was 100% for MR vs. 70% for RR patients
(p = 0.0002). There were 2 patients with grade III-IV tox-
icity (1 neutropenia, 1 encephalopathy) in MR group. In
conclusion, this planed subgroup analysis for non-FL
patients revealed significant benefits in TTF and TTTC.
These results in non-FL differ from those of FL
patients in this trial. The overall response rate to R in-
duction was higher in FL patients (FL 71% vs. non-FL
41%; p < .0001), but no TTF benefit was observed with
MR for FL patients.
Rituximab: study of pharmacokinetics (PK) and
pharmacodynamics (PD) for faster infusion
Rituximab (R) is typically infused over 4–6 hours. Faster
infusion can improve patient’s convenience and optimize
utilization of oncology unit resources. A prospective,
open-label, multicenter, single-arm trial was conducted
to assess the safety, PK and PD of a 90-min infusion rate
for R in NHL patients [29]. Patients (≥18 yrs old) with
untreated DLBCL or FL received R-chemotherapy at the
standard infusion rate (4–6 h) in cycle 1. Further R infu-
sion was given over 90-min to patients who had no
severe reactions and had circulating lymphocyte
counts≤ 5000/μl prior to cycle 2. A total of 14 patients
who completed all cycles with faster infusion were asked
to provide further serum samples up to 16 weeks after
the last chemotherapy cycle. PK parameters, including R
terminal half-life (t½), maximum serum concentration
(Cmax), systemic clearance (CL) and volume of distribu-
tion (V) were evaluated. A total of 365 patients received
the 90-min infusion rate at cycle 2. Peak R levels were
higher than seen in published data of q3w R regimens
but comparable with levels seen for q1w R regimens.
The PK data and B cell (CD19+) depletion were similar
between the groups of faster infusion and standard rate.
These results suggest that a faster infusion of R has simi-
lar safety and PK data to the standard infusion rate. It is
however important to evaluate the efficacy and the long-
term outcome of the lymphoma treated at the faster in-
fusion rate.
R-CVP vs R-CHOP vs R-FM: the final analysis of
FOLL05 trial
There has been no international consensus on frontline
optimal chemotherapy regimen for patients with
advanced follicular lymphoma (FL). A final report of
FOLL05 trial was presented at 2012 ASCO on a rando-
mized comparison of R-CVP x 8 vs R-CHOP x 6 vs
R-FM x 6 [30]. Maintenance therapy was not allowed in
this randomized trial. The primary end point was timeto treatment failure (TTF) which was defined as failure
of induction therapy, progressive or relapse disease and
death from any causes. A total of 534 patients were en-
rolled; 30 were not evaluable. The patients’ characteris-
tics were as the following: median age = 56 years (range
30–75), 63% of patients had stage IV disease, 37% had
unfavorable disease (FLIPI score 3–5).
There was no significant difference of overall response
rate (CR +PR) for the whole group (91%, p = 0.247). The
median follow-up time was 34 months. The 3-year TTF
for patients treated with R-CVP, R-CHOP and R-FM
was 46%, 64% and 61%, respectively (R-CHOP vs R-CVP
p= 0.007; R-FM vs R-CVP p= 0.021; R-FM vs R-CHOP
p= 0.969). Therefore, R-CVP had the worst TTF among
the three groups.
The 3-year overall survival rate (OS) was not signifi-
cantly different among the three groups (R-CVP 98%,
R-CHOP 95%, and R-FM group 93%). Patients in R-FM
group had a higher rate of severe neutropenia (64% vs
28% R-CVP, p < 0.001; vs 50% R-CHOP, p = 0.015).
At this final analysis, a total of 23 patients developed
secondary malignancies (R-CVP 2%, R-CHOP 3% and
R-FM 8%), indicating a higher incidence of secondary
malignancies in R-FM group.
In summary, R-CHOP appears to be the best among
the three with regard to the risk-benefit consideration
for frontline therapy of advanced follicular lymphoma.
One weakness of the trial was that it used CT instead of
more sensitive PET scan to define complete response. In
addition, TTF could have been improved if maintenance
therapy was included [3,31].BR vs R-CHOP: StiL NHL1 trial update
Bendamustine has been used for frontline treatment of
CLL and for relapsed /refractory indolent lymphoma
[32-36]. However its role in frontline therapy of indolent
lymphoma has not been established. BR was compared
with R-CHOP in a multicenter, randomized, phase III
study for first-line treatment, the StiL NHL1 trial [37].
Patients with newly diagnosed indolent lymphoma and
mantle cell lymphoma were enrolled. An updated ana-
lysis with a cut-off date for 31 Oct 2011 was presented
at 2012 ASCO. The primary endpoint was PFS. Patients
received a maximum of 6 cycles after randomization.
The study enrolled 549 patients, 514 of them were eva-
luable (261 BR; 253 R-CHOP). The median age was
64 years.
The median follow-up was 45 months at this update.
The PFS of BR was more than doubled in comparison
with that of R-CHOP (69.5 versus 31.2 months; HR 0.58,
95% CI 0.44–0.74; p < 0.001). This advantage of BR was
seen across all histological subtypes except marginal
zone lymphoma. This advantage of BR was true both for
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patients >60 years (n = 315, HR 0.62, P = 0.002).
This update also reported more results based on risk
factors. Compared with R-CHOP, BR significantly pro-
longed PFS in patients with normal LDH (P< 0.001). The
longer PFS with BR was seen in both favorable (0–2 fac-
tors, p = 0.043) and unfavorable (3–5 factors, p = 0.068)
FLIPI subgroups of patients with follicular lymphoma.
There were 74 treatment failures in the BR group, 116
in the R-CHOP group. In the R-CHOP group, 45% (52/
116) received BR as salvage regimen. There was no signifi-
cant difference in overall survival. Previously there have
been unanswered questions regarding long-term compli-
cations with bendamustine. At this update, more informa-
tion was provided in terms of secondary malignancies.
With a median follow-up of 45 months, there appears to
have no significant differences for secondary malignancies
between the two groups (20 in BR, 23 in R-CHOP). In
particular, there was one hematological malignancy in
each group (1 MDS in BR, 1 AML in R-CHOP).
With this updated analysis, it appears that for newly
diagnosed indolent lymphoma and elderly patients with
MCL, BR has longer PFS and is better tolerated than R-
CHOP. Long-term complications with secondary malig-
nancies appear to be comparable.
R-CHOP vs CHOP-I131 tositumomab
Two agents have been approved for lymphoma radioim-
munotherapy[38-45]. SWOG and CALGB intergroup
trial, S0016, enrolled 554 patients between 3/1/2001 and
9/15/2008 to compare the safety and efficacy of 2 immu-
nochemotherapy regimens, R-CHOP vs CHOP-I131 tositu-
momab (CHOP-RIT), for untreated patients with bulky
stage II, III or IV FL[46]. Patients were randomized to
CHOP-R x 6 or CHOP-RIT X 6. Both treatment regimens
had excellent outcome with no significant differences (2 yr
PFS: CHOP-R 76% vs CHOP-RIT 80%, p =0.11; 2 yr OS:
CHOP-R 97% vs CHOP-RIT 93%, p =0.08). The serum-
β2M, LDH level, and FLIPI score were found to be the
strongest prognostic factors for PFS and OS by multivari-
able analysis.
Gemcitabine, rituximab and oxaliplatin (GROC)
Oxaliplatin has been studied for lymphoma therapy in
various combination regimens [47-50]. Recently, in the
salvage setting for relapsed/refractory NHL, gemcitabine,
rituximab and oxaliplatin (GROC) was shown in a phase
II trial to have an overall response rate of 58%, grade 3–4
thrombocytopenia of 9% and neutropenic fever of 3.5%
[51]. No severe non-hematologic toxicities were observed.
Patients received rituximab (375 mg/m2) on day 1. On day
2, patients received gemcitabine (1000 mg/m2) and oxali-
platin (100 mg/m2). This was repeated every two weeks. A
total of 58 patients were enrolled. The median age was72 years (range 24 to 88 years). Median PFS was 134 days
(95% CI 115–153) and median OS was 296 days (95% CI
164–428). The risk factors of age, IPI, LDH and albumin
level did not influence the responses, but prior rituximab
(p= 0.02) and response to initial therapy (p= 0.04) corre-
lated with better outcomes. Therefore, GROC may be a
useful salvage regimen for relapsed/refractory NHL. After
complete of GROC therapy, 9 patients were successfully
mobilized, collected and transplanted.
Conclusions and future directions
The optimal chemotherapy regimen for frontline therapy
of advanced indolent lymphoma remains uncertain.
Compared with R-CVP and R-FM, R-CHOP appears to
have the best risk-benefit ratio. The StiL NHL1 trial
showed that BR has longer PFS and is better tolerated
than R-CHOP. Long-term complications with secondary
malignancies between the two regimens appear to be
comparable. Many novel agents with different mechan-
isms of action are being explored [52-55]. The Bruton’s
tyrosine kinase inhibitors appear to be very active in
chronic lymphoid leukemia and refractory lymphoma
[56-59]. It would be interesting to see whether adding
novel agents to BR or R-CHOP can further improve the
outcomes of advanced indolent lymphoma.
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